强迫症神经生物学与治疗的整合
本文综述强迫症(OCD)的神经生物学与治疗研究进展。暴露反应预防与5-羟色胺再摄取抑制剂(SRI)是仅有的确立一线治疗,但部分患者无效且完全缓解者少。抗精神病药增效是SRI单药外唯一有实质实证支持的药物方案。遗传、谷氨酸系统、皮质-纹状体-丘脑-皮质(CSTC)环路及神经调控研究为病理生理与治疗提供线索。
要点
- OCD一线治疗为暴露反应预防与SRI;抗精神病药增效是唯一有实质实证支持的药物增效方案。
- 多项研究支持遗传对OCD有显著贡献,但具体遗传决定因素尚需进一步研究。
- CSTC环路活动增高证据一致,多种干预可能共同调节该环路。
核心结论
- OCD是常见、慢性且常致残的疾病,现有治疗对部分患者无效且完全缓解者少。
- SRI在OCD中的优先疗效未导致发现5-羟色胺能异常或开发新5-羟色胺能药物。
- 多种干预(药物、行为或设备)的共同底物可能是对CSTC环路的调节。
研究设计与样本
- 本文为综述,聚焦有助于阐明OCD病理生理并推进治疗的研究领域。
主要发现
- 多项研究支持遗传对OCD有显著贡献,但确定具体遗传决定因素需进一步研究。
- 多条临床前与临床证据提示OCD存在谷氨酸系统功能障碍,促使测试若干有前景的谷氨酸调节剂。
- OCD功能影像研究一致显示构成CSTC环路脑区活动增高。
- 非侵入性设备(如经颅磁刺激)或侵入性操作(如深部脑刺激)的神经调控治疗进一步支持CSTC模型。
关键数值与推荐
- OCD唯一确立的一线治疗为暴露反应预防与SRI。
- 除SRI单药外,抗精神病药增效是唯一有实质实证支持的OCD药物方案。
临床怎么用
- 临床可依据综述将暴露反应预防与SRI作为OCD一线治疗。
- 对SRI单药疗效不足者,可考虑抗精神病药增效作为有实证支持的药物策略。
- 谷氨酸调节剂与神经调控为研究性方向,需结合CSTC环路模型理解干预机制。
局限性
- 对OCD神经生物学的理解不完整,妨碍新治疗开发或现有干预增强。
- 具体遗传决定因素尚未明确,需进一步研究。
- SRI优先疗效未转化为5-羟色胺能异常发现或新药开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obsessive-compulsive disorder (OCD) is a common, chronic, and oftentimes disabling disorder. The only established first-line treatments for OCD are exposure and response prevention, and serotonin reuptake inhibitor medications (SRIs). However, a subset of patients fails to respond to either modality, and few experience complete remission. Beyond SRI monotherapy, antipsychotic augmentation is the only medication approach for OCD with substantial empirical support. Our incomplete understanding of the neurobiology of OCD has hampered efforts to develop new treatments or enhance extant interventions. This review focuses on several promising areas of research that may help elucidate the pathophysiology of OCD and advance treatment. Multiple studies support a significant genetic contribution to OCD, but pinpointing the specific genetic determinants requires additional investigation. The preferential efficacy of SRIs in OCD has neither led to discovery of serotonergic abnormalities in OCD nor to development of new serotonergic medications for OCD. Several lines of preclinical and clinical evidence suggest dysfunction of the glutamatergic system in OCD, prompting testing of several promising glutamate modulating agents. Functional imaging studies in OCD show consistent evidence for increased activity in brain regions that form a cortico-striato-thalamo-cortical (CSTC) loop. Neuromodulation treatments with either noninvasive devices (e.g., transcranial magnetic stimulation) or invasive procedures (e.g., deep brain stimulation) provide further support for the CSTC model of OCD. A common substrate for various interventions (whether drug, behavioral, or device) may be modulation (at different nodes or connections) of the CSTC circuit that mediates the symptoms of OCD.
引用
- Goodman WK, Storch EA, Sheth SA, et al. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2021. PMID: 33384007. doi:10.1176/appi.ajp.2020.20111601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。